A PHASE 3 LUNG-FIBROSIS DRUG PRESERVED BREATHING BETTER THAN PLACEBO.
The lower dose met the trial’s main goal over 52 weeks. The higher dose did not, and the detailed results are not yet published.
The lower dose of experimental drug adimilparant met the primary endpoint in a large Phase 3 idiopathic pulmonary fibrosis trial, slowing the loss of lung function compared with placebo over one year.
WHAT HAPPENED
The ALOFT-IPF trial enrolled 1,255 people with idiopathic pulmonary fibrosis. Bristol Myers Squibb reported that the 60 mg dose met the primary endpoint of preserving forced vital capacity over 52 weeks compared with placebo. The 120 mg dose did not meet that endpoint.
These are topline results. The company has not yet released the full numerical dataset for independent review, and the treatment remains experimental. The signal matters because idiopathic pulmonary fibrosis progressively scars the lungs and has limited treatment options.
WHY THIS IS HOPESLOP
Progress in a hard disease often arrives as “slower decline,” not a cure. For people whose breathing worsens year by year, preserving lung function is a clinically meaningful target—and a Phase 3 result is a reason to look closely at the full data when they arrive.
ORIGINAL SOURCEReuters / Bristol Myers SquibbRead the original report
A DAILY ALLEGATION OF PROGRESS.
One good thing from the internet, every day. Nothing else.